- In September 2024, BioCryst Pharmaceuticals, Inc. announced that it has been awarded a contract by the U.S. Department of Health and Human Services (HHS) valued at up to $69 million. This contract will cover the procurement of up to 95,625 doses of RAPIVAB (peramivir injection) over a five-year period for the treatment of influenza
- In October 2023, Vir Biotechnology, Inc. announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS) Administration for Strategic Preparedness and Response (ASPR), awarded Vir approximately $50 million in new funding. The funding will support the advancement of novel monoclonal antibody (mAb) candidates and delivery solutions to enhance the use of mAbs in the treatment of COVID-19 and bolster pandemic preparedness and response
- In July 2023, Roche Diagnostics India announced the launch of Elecsys HCV Duo, India’s first fully automated immunoassay that enables the simultaneous and independent detection of both hepatitis C virus (HCV) antigen and antibody status from a single plasma or serum sample. The Elecsys HCV Duo assay enables significantly earlier (~3 weeks earlier) diagnosis of active hepatitis C virus infection compared to using antibody-only tests
- In January 2023, Thermo Fisher Scientific announced the launch of its CE-IVD-marked Applied Biosystems TaqPath Seq HIV-1 Genotyping Kit, a Sanger sequencing-based assay designed to analyze positive HIV samples and identify genetic variants that could confer resistance to commonly used antiretroviral therapies
- In December 2021, Roche completed the acquisition of TIB Molbiol to expand its PCR-test portfolio in the fight against emerging infectious diseases. Roche and TIB Molbiol built upon their capabilities for the rapid development of assays to detect emerging pathogens and potential health threats, including infectious diseases
